falsefalse

Optimizing Treatment for HR+/HER2- Breast Cancer: A Multidisciplinary Approach - Episode 12

Unmet Needs in the Treatment of HR+/HER2- Breast Cancer

, , ,

Closing their discussion, the panel shares some remaining unmet needs in the treatment and management of patients with HR+/HER- breast cancer.

Current Time 0:00
Duration 0:00
Loaded: 0%
Stream Type LIVE
Remaining Time 0:00
 
1x
  • Chapters
  • descriptions off, selected
  • captions off, selected
    EP. 1: Importance of Multidisciplinary Care for Patients With HR+/HER- Breast Cancer
    EP. 2: Barriers to Optimal Care in Patients With HR+/HER- Breast Cancer
    EP. 3: Clinical Scenario: A 60-Year-Old Woman With Newly Diagnosed Breast Cancer
    EP. 4: Considerations for Chemotherapy Dosing in Patients With HR+/HER- Breast Cancer
    EP. 5: Helping Patients With HR+/HER2- Breast Cancer Access Abemaciclib
    EP. 6: Updates in Adjuvant Therapy for HR+/HER- Breast Cancer From ASCO 2023: The NATALEE Trial
    EP. 7: Monitoring and Treating Lymphedema in Patients With HR+/HER- Breast Cancer
    EP. 8: Frontline CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer
    EP. 9: Considerations for Use of CDK4/6 Inhibitors in HR+/HER2- Metastatic Breast Cancer
    EP. 10: Common Toxicities of CDK4/6 Inhibitors in Patients With HR+/HER2- Metastatic Breast Cancer
    EP. 11: Utility of Primary Tumor Surgery for De Novo Metastatic Breast Cancer
    Now Viewing
    EP. 12: Unmet Needs in the Treatment of HR+/HER2- Breast Cancer

    Related Content:

    Optimizing Treatment for HR+/HER2- Breast Cancer: A Multidisciplinary ApproachInsightsInsights Video SeriesBreast Cancer
    CHMP Shares Positive Opinion for Denosumab Biosimilars for Osteoporosis and Skeletal-Related Cancer Complications
    Dr Hamilton on Vepdegestrant vs Fulvestrant in ER+/HER2-Negative Advanced Breast Cancer
    Higher Pretreatment HER2 Amplicon mRNA Signature Predicts Improved Outcomes With Trastuzumab Deruxtecan in Metastatic Breast Cancer
    x